$100 million Euros to find Ebola cure
Johnson & Johnson announced that 100 million euros ($115 million) would be given from Europe’s Innovative Medicines Initiative to speed up work on developing Ebola vaccine.
This follows the drugmaker’s announcement earlir this month that it had begun clinical trials of its two-injection vaccine.
J&J has been seeking partners after committing up to $200 million to accelerate its Ebola vaccine program in October.
The new initiative will see J&J join with institutions including the London School of Hygiene & Tropical Medicine, the University of Oxford and the Institut National de la Sante et de la Recherche Medicale to form consortia working on different aspects of vaccine development.